All In Biotech

Drug Trial Radar · NCT05999513

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 21, 2023

Primary completion

Oct 31, 2023

Study completion Oct 31, 2023

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan tablet versus the casdatifan capsule, and to evaluate the effect of food on the single-dose PK of casdatifan tablet in healthy adult volunteers.

Conditions

  • Healthy Participants

Interventions

  • casdatifanDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Drug Concentration-Time Curve (AUC)Time frame: Predose, Up to 168 hours postdose
  2. Maximum Concentration (Cmax)Time frame: Predose, Up to 168 hours postdose
  3. Time to Maximum Concentration (Tmax)Time frame: Predose, Up to 168 hours postdose
  4. Terminal Half-Life Time (t1/2)Time frame: Predose, Up to 168 hours postdose
  5. Apparent Total Plasma Clearance (CL/F)Time frame: Predose, Up to 168 hours postdose
  6. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F)Time frame: Predose, Up to 168 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc.

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.